DiPLA
Pharmaceutical compound
From Wikipedia, the free encyclopedia
DiPLA, also known as N,N-diisopropyllysergamide or as lysergic acid diisopropylamide, is a putative serotonergic psychedelic of the lysergamide family related to lysergic acid diethylamide (LSD).[1][2][3][4] It is the analogue of LSD in which the N,N-diethyl groups have been replaced with N,N-diisopropyl groups.[3][2][5]
- None
 | |
 | |
| Clinical data | |
|---|---|
| Other names | DiPLA; N,N-Diisopropyllysergamide; Lysergic acid diisopropylamide |
| Drug class | Serotonin receptor modulator; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C22H29N3O |
| Molar mass | 351.494 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Use and effects
Interactions
Pharmacology
Pharmacodynamics
In an early study, DiPLA showed 23.2% of the antiserotonergic activity of LSD in the isolated rat uterus and hence was about 4-fold less potent than LSD in this assay.[3][4][7] Subsequently, DIPLA was reported to have an affinity (Ki) for the serotonin 5-HT2A receptor of 9.0 to 20.2 nM, which was about 4- to 9-fold lower than that of LSD (Ki = 4.8 nM).[8][2][5][9] It is an agonist of the serotonin 5-HT2A receptor and also interacts with other receptors such as the serotonin 5-HT1A receptor, the serotonin 5-HT2C receptor, and dopamine receptors.[8][1] DIPLA fully substituted for LSD in rodent drug discrimination tests, suggesting that it could have psychedelic effects in humans.[2][9] Unlike other assessed lysergamides however, DIPLA was much less potent than LSD, about 8-fold so in the drug discrimination test.[5][9]
History
DiPLA was first described in the scientific literature by Albert Hofmann and colleagues by 1955.[10][11] Subsequently, it was studied in more detail by David E. Nichols and colleagues in the 1990s and thereafter.[2][5][9][1]